Publications

Back to Publications

Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.

This activity is supported by an educational grant from AstraZeneca.

Low-dose Interleukin-2 Therapy in Active Systemic Lupus Erythematosus (LUPIL-2): A Multicentre, Double-blind, Randomised and Placebo-controlled Phase II Trial

Ann Rheum Dis. 2022;81:1685–1694

Following evidence of associated disturbances in Treg homeostasis playing a crucial role in the pathogenesis of SLE, but no currently approved treatments that address the modulation of Treg biology, Humrich, et al. evaluate the efficacy of low-dose IL-2 therapy in patients with moderate-to-severe SLE disease activity, receiving standard treatment.

Keywords:


LinkedIn